Projects
Search from 1147 projects:
1147 Project(s)
Colchicine in Patients at Cardiac Risk undergoing Major Non-Cardiac Surgery: prospective, randomized, triple-blinded, placebo-controlled, multi-centre study
Nov 1, 2024
Clinical Studies - Nov 1, 2024 - Sep 30, 2027
Scheduled
Project leader: Filipovic Miodrag, Yurttas Timur
Members: Klein Carsten, Keller Mirja
A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Oct 1, 2024
Clinical Studies - Oct 1, 2024 - Dec 31, 2029
Scheduled
Project leader: Ehl Niklas
Members: Vetsch Susanne
Humoral immunity and risk factors for Alongshan-virus in healthcare workers from Eastern Switzerland –proposal for a seroepidemiologic analysis
Aug 1, 2024In dieser prospektiven Studie innerhalb der SURPRISE+ Kohorte möchten wir die Seroprävalenz und Serokonversion gegen das Alongshan-Virus (ALSV). ALSV ist ein Flavivirus, welches ein FSME-ähnliches Krankheitsbild auslösen kann. Das Virus wird häufig i...
Clinical Studies - Aug 1, 2024 - Feb 28, 2026
Ongoing
Project leader: Kohler Philipp
Members: Frischknecht Manuel, Kuster Stefan, Kahlert Christian
Textile ECG electrodes for long-term monitoring (Tex3CG)
Jul 1, 2024The objective of this project is to evaluate and compare the signal quality of electrocardiogram (ECG) signals acquired by adhesive textile ECG electrodes (Tex) using adhesive gel electrodes (Gel) as a reference system.
Clinical Studies - Jul 1, 2024 - Dec 31, 2024
Ongoing
Project leader: Annaheim Simon, Ammann Peter
Members: Meier Jessica
Hemodynamic characteristics of bendopnea – pathophysiological basis of a novel symptom in heart failure patients
Jul 1, 2024The present project has several objectives. Our main goal is to evaluate the hemodynamic characteristics in particular the mean pulmonary artery wedge pressure (mPAWP) of patients with versus without bendopnea and those with high (supramedian) vers...
Clinical Studies - Jul 1, 2024 - Jun 30, 2026
Ongoing
Project leader: Maeder Micha
Members: Schneider Irene
A first-in-human, open-label, multicenter Phase l/ll study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
Jun 13, 2024
Clinical Studies - Jun 13, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Sennhauser Andrina, Müller Fiona
Shunt-dependency after aneurysmal subarachnoid haemorrhage – the role of early hyperglycaemia in cerebro-spinal fluid and blood
May 26, 2024Several factors influence morbidity after aneurysmal subarachnoid haemorrhage (aSAH) and therefore also functional outcome. One of these factors is hydrocephalus (HCP) which, in case of unsuccessful weaning from an extraventricular drain (EVD) can le...
Clinical Studies - May 26, 2024 - Sep 1, 2027
Ongoing
Project leader: Hostettler Isabel
Members: Wiebe Lauren, Pietsch Urs, Klein Carsten, Keller Mirja, Kälin Vincens, Yildiz Yesim
FANTOM
May 6, 2024To evaluate the continued safety and performance of the Reva Fantom Sirolismus-Eluting Bioresorbable Coronary Scaffold in nativ coronary arteries that includes incorporation of a deformable expansion technologgy and an enhanced scaffold material (Tyr...
Clinical Studies - May 6, 2024 - Jun 30, 2030
Ongoing
Project leader: Rigger Johannes
Members: Fink Karin, Schneider Irene
Novel screening assay for novel psychoactive substances
May 1, 2024Consumption of so-called novel psychoactive substances (e.g. “synthetic opioids” and “synthetic cannabinoids”) is a growing global health threat. Due to the rapid market dynamics of the new drugs of abuse market current analytical methods cannot keep...
Fundamental Research - May 1, 2024 - Apr 30, 2025
Scheduled
Project leader: Moosmann Björn
Point Prevalence of Antibiotic Resistance in Helicobacter pylori in St. Gallen: An Observational Pilot Trial
May 1, 2024Evaluation der Antibiotika-Resistenz von Helicobacter pylori Magen und Überprüfung der Konsistenz von Resistenzdaten aus dem Stuhl und aus Magenbiopsien
Clinical Studies - May 1, 2024 - Jun 30, 2025
Scheduled
Project leader: Kueres-Wiese Alexander
Members: Kuster Stefan, Frei Nicola Fabian, Borovicka Jan
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
Apr 18, 2024
Clinical Studies - Apr 18, 2024 - Dec 31, 2028
Completed
Project leader: Hitz Felicitas
Members: Bürki Ramona, Quinter Janine
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The DANTE Trial A Trial of AIO in collaboration with SAKK
Apr 17, 2024
Clinical Studies - Apr 17, 2024 - Dec 31, 2028
Ongoing
Project leader: Weisshaupt Christian
Members: Müller Fiona, Kehl Jeanine
Drainageflüssigkeitssensor zur Früherkennung von Anastomosenlecks
Apr 3, 2024Die Studie hat zum Ziel, Eigenschaften von abdominaler Drainageflüssigkeit von Patientinnen/Patienten, die sich einer Pankreas-, Ösophagus- oder Rektumoperation unterzogen haben, zu charakterisieren. In einem Folgeschritt soll die Korrelation einer S...
Clinical Studies - Apr 3, 2024 - Mar 31, 2025
Ongoing
Project leader: Tarantino Ignazio
Members: Seiler Edith, Matzinger Marlene
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Mar 25, 2024
Clinical Studies - Mar 25, 2024 - Dec 31, 2028
Ongoing
Project leader: Hess Dagmar
Members: Hutter Franziska, Quinter Janine
CELIA (Phase 2)
Mar 1, 2024A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Clinical Studies - Mar 1, 2024 - Dec 31, 2026
Ongoing
Project leader: Felbecker Ansgar
Members: Göhl-Freyn Kristina
Large language models for the identification of etiotypes in Chronic Obstructive Lung Diseases
Mar 1, 2024Recent guidelines proposed new taxonomic classifications for COPD, so-called etiotypes, which have clinical relevance for management and treatment of patients. This project hypothesizes that information extracted from patients' electronic health reco...
Fundamental Research - Mar 1, 2024 - Feb 28, 2025
Ongoing
Project leader: Baty Florent
Members: Brutsche Martin, Albrich Werner, Hastings Janna, Kozu Kei, Toromanovic Tim
Memory Clinic Cohort Study
Mar 1, 2024Dementia is a clinical syndrome defined by a progressive cognitive decline interfering with a person's daily life and activities which is caused by a group of heterogenous neurodegenerative and neurovascular diseases which often overlap. Since patho...
Clinical Studies - Mar 1, 2024 - Dec 31, 2040
Ongoing
Project leader: Schneider Thomas, Felbecker Ansgar
Members: Göhl-Freyn Kristina, Schilg-Hafer Lenka
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management. The MINERVA Trial – A phase IV Trial
Feb 29, 2024In der Minerva-Studie erhalten die Patientinnen das Medikament Abemaciclib entsprechend der Zulassung in Kombination mit einem Aromatasehemmer oder Fulvestrant als endokrine Therapie. Die Wahl der passenden endokrinen Therapie trifft der Prüfarzt/ di...
Clinical Studies - Feb 29, 2024 - Dec 31, 2028
Ongoing
Project leader: Huober Jens
Members: Radovanovic Suzana, Müller Fiona
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
Feb 1, 2024
Clinical Studies - Feb 1, 2024 - Apr 4, 2027
Ongoing
Members: Neuwirth Christoph
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Jan 26, 2024
Clinical Studies - Jan 26, 2024 - Dec 31, 2027
Ongoing
Project leader: Aeppli Stefanie
Members: Scherrer Julia, Quinter Janine